PAS
OKUR

Point72 Asia (Singapore)’s OnKure Therapeutics OKUR Stock Holding History

Point72 Asia (Singapore)’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-967
Closed -$16.4K – 1284
2024
Q3 		$16.4K Sell
967
-836
-46% -$12.4K ﹤0.01% 836
2024
Q2 		$27.2K Buy
+1,803
New +$30.6K 0.01% 783

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Point72 Asia (Singapore)'s OKUR Position: Q4 2024 in Review

Point72 Asia (Singapore) sold out of OnKure Therapeutics (OKUR) in Q4 2024, closing a stake of 967 shares — an estimated $16.4K sold.

Point72 Asia (Singapore) first reported a position in OKUR in Q2 2024 and held it in 2 quarters. The position peaked at $27.2K in Q2 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q4 2024.

  • Point72 Asia (Singapore) reported no remaining OnKure Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 967 OnKure Therapeutics shares in Q4 2024, an estimated $16.4K.
  • Point72 Asia (Singapore) first reported a position in OnKure Therapeutics in Q2 2024 and held it in 2 quarters.
  • Point72 Asia (Singapore)'s OnKure Therapeutics position peaked at $27.2K in Q2 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q4 2024, filed 14 Feb 2025.